Bio News
Sanofi will invest $294 million (approximately 426.3 billion won) to expand its AI hub in Toronto, Canada, with the goal of cutting drug development time in half. The investment is expected to create 50 specialized jobs by 2028, and the company plans to apply AI technology across the drug development process, from discovery through manufacturing and commercialization. Sanofi has already secured U.S. Food and Drug Administration (FDA) approval for a therapy using an AI-based “digital twin.”
BIOBOOK TEAM
biobookmedia@biobook.co.krBrazilian Health Regulatory Agency Approves Gazyva for a New Indication in Systemic Lupus Erythematosus
Belgium’s Amadcell acquires two Lakefront CAR T therapies for up to $230 million
OrbiMed Raises $3 Billion, Its Largest Asia Fund to Date
UK Researchers Identify New Mechanism of Antifungal Drug Resistance in Candida auris
AstraZeneca Signs $1.5 Billion AI Drug Target Discovery Deal With Insitro
Hyundai Pharmaceutical’s Third-Quarter Operating Profit Reaches KRW 5.937 Billion, Up 44% Year Over Year
